These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32799907)

  • 1. Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study.
    Sharma SK; Jain S; Bahl P; Potturi P; Rathi M; Naidu S; Sachdeva N; Dhir V; Jain S
    Arthritis Res Ther; 2020 Aug; 22(1):189. PubMed ID: 32799907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
    BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
    Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K; Zintzaras E; Tzioufas AG
    Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
    Mok CC
    Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
    Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
    J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
    Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil vs. cyclophosphamide-based induction regimens for lupus nephritis: Outcomes at a tertiary care centre in Lahore, Pakistan.
    Saeed MA; Khan A; Naeem F; Ahmad NM
    J Pak Med Assoc; 2024 May; 74(5):868-873. PubMed ID: 38783432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
    Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
    Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
    Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
    Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis.
    Ruiz-Irastorza G; Dueña-Bartolome L; Dunder S; Varona J; Gomez-Carballo C; Dominguez-Cainzos J; Rodrigo-Manjon A; Bueno L; Richez C; Duffau P; Blanco P; Lazaro E
    Autoimmun Rev; 2021 Oct; 20(10):102898. PubMed ID: 34274543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
    Mendonca S; Gupta D; Ali S; Gupta P
    Saudi J Kidney Dis Transpl; 2017; 28(5):1069-1077. PubMed ID: 28937065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
    Chbihi M; Eveillard LA; Riller Q; Brousse R; Berthaud R; Quartier P; Salomon R; Charbit M; Avramescu M; Biebuyck N; Dehoux L; Garcelon N; Duong-Van-Huyen JP; Bader-Meunier B; Boyer O
    J Nephrol; 2023 Apr; 36(3):829-839. PubMed ID: 36208405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
    Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
    Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis.
    Lee YH; Song GG
    Pharmacology; 2022; 107(9-10):439-445. PubMed ID: 35609529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.